Case-Based Roundtable Meetings Spotlight: September 2022

At a live virtual event, Saketh Guntupalli, MD, discussed with participants the role of PARP inhibitors in the first-line setting for patients with advanced ovarian cancer.

During a Targeted Oncology case-based roundtable event, Saad Z. Usmani, MD, MBC, discussed the case of a patient who progressed on first- and second-line therapy for multiple myeloma and did not receive a stem cell transplant.

During a Targeted Oncology case-based roundtable event, Timothy M. Kuzel, MD, discussed the treatment options for patients with clear cell renal cell carcinoma.

During a case-based roundtable event, Javier L. Munoz, MD, MBA, discussed data supporting the use of newer therapies for patients with relapsed/refractory diffuse large B-cell lymphoma.

Richard S. Finn, MD, led a discussion on the management of patients with advanced hepatocellular carcinoma.

Anthony Mato, MD, discusses the case of a 76-year-old man with stage IV chronic lymphocytic leukemia.

Elisabet E. Manasanch, MD, MHSc led a discussion on treating relapsed/refractory multiple myeloma with BCMA targeted therapy.

During a Targeted Oncology case-based roundtable event, Erika P. Hamilton, MD, discussed the choice of first- and second-line therapy for a patient with triple-negative breast cancer following adjuvant chemotherapy.

During a Targeted Oncology case-based roundtable event, Andrew Kuykendall, MD, discussed the treatment options for a patient with myelofibrosis based on factors including platelet count.

During a Targeted Oncology case-based roundtable event, Chung-Han Lee, MD, PhD, discussed the latest data supporting the use of lenvatinib/pembrolizumab as frontline therapy for patients with advanced clear cell renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Wade T. Iams, MD, discussed the case of a patient who progressed following a partial response to platinum-based chemotherapy for extensive-stage small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Cristina Gasparetto, MD, discussed data supporting the use of selinxor for patients with relapsed/refractory multiple myeloma.